{"page_content": "Find out more on  \nzealandpharma.com\nCHI\nCongenital hyperinsulinism \n(CHI) is a rare disease affecting \nmainly newborns and toddlers. It \nis caused by a defect in pancreatic \nbeta-cells, resulting in insulin \noverproduction and leading to \npersistent and dangerously low \nblood sugar levels. CHI develops \nin one out of 50,000 (or fewer) \nchildren, which corresponds \nto approximately 300 children \ndiagnosed in the U.S. and Europe \nevery year.\u00b9,\u00b2The most severely affected children need to have their \npancreas surgically removed within a few months of birth in order to prevent hypoglycemia. This invariably results in the development of type 1 diabetes, which will follow them for the rest of their lives.\u00b3 \nCurrent treatment options are insufficient: less than one-\nthird of newborns and less than two-thirds of older chil-dren respond to approved medical therapy. The burden of disease is significant not just for the affected children but for their families and caregivers and represents a signifi-cant unmet medical need.\u207421\nZealand Pharma  \u221e  Annual Report 2021CHI", "metadata": {"source": "NASDAQ_ZEAL_2021.pdf", "page": 20, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}